ଟାଫେନୋକ୍ୱିନ

ଟାଫେନୋକ୍ୱିନ
Clinical data
Trade names	Krintafel, Arakoda, others
Synonyms	Etaquine, WR 238605, SB-252263
AHFS/Drugs.com	Krintafel monograph; Arakoda monograph
MedlinePlus	a618050
data	US DailyMed: Tafenoquine;
Pregnancy; category	AU: C ; US: N (Not classified yet) ;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name N-[2,6-Dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine;
Chemical and physical data
Formula	C24H28F3N3O3
Molar mass	463.493
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c3cc(Oc1c(OC)cc(NC(C)CCCN)c2nc(OC)cc(c12)C)ccc3;
	InChI InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3 ; Key:LBHLFPGPEGDCJG-UHFFFAOYSA-N ;
(verify)

ଟାଫେନୋକ୍ୱିନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ କ୍ରିଣ୍ଟାଫେଲ, ଏକ ଔଷଧ ଯାହା ମ୍ୟାଲେରିଆର ପ୍ରତିଷେଧ ଏବଂ ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ | ^[୩] ପ୍ଲାଜମୋଡ଼ିଅମ ଭାଇଭାକ୍ସ ଜନିତ ତୀବ୍ର ମ୍ୟାଲେରିଆର ପୁନଃ ଆକ୍ରମଣର ପ୍ରତିଷେଧ ପାଇଁ ଏହା ଅନ୍ୟାନ୍ୟ ଔଷଧ ସହିତ ମିଳିତ ଭାବରେ ବ୍ୟବହୃତ ହୁଏ | ^[୪] ସମସ୍ତ ପ୍ରକାର ମ୍ୟାଲେରିଆକୁ ରୋକିବା ପାଇଁ ଏହା ବ୍ୟବହୃତ ହୋଇପାରେ | ^[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ | ^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବାନ୍ତି, ମୁଣ୍ଡବିନ୍ଧା ଏବଂ ମୁଣ୍ଡ ବୁଲାଇବା ହୋଇପାରେ | ^[୫] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମେଥେମୋଗ୍ଲୋବିନେମିଆ, ଶୋଇବାରେ ଅସୁବିଧା ଏବଂ ଆନାଫାଇଲକ୍‌ସିସ ହୋଇପାରେ | ^[୬] ଜି୬ପିଡି ଅଭାବ ଥିବା ଲୋକଙ୍କଠାରେ ଲୋହିତ ରକ୍ତ କଣିକା ଭାଙ୍ଗି ଯାଇପାରେ ।^[୬] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କରିବା ସୁପାରିଶ କରାଯାଏ ନାହିଁ | ^[୬] ଏହା ୮-ଆମିନୋକ୍ଇନୋଲିନ ଶ୍ରେଣୀର ଏକ ଔଷଧ | ^[୩] ଏହା କିପରି କାମ କରେ ତାହା ଅସ୍ପଷ୍ଟ କିନ୍ତୁ ଏହା ଉଭୟ ଯକୃତ ଏବଂ ରକ୍ତରେ ପ୍ରଭାବଶାଳୀ ଥାଏ | ^[୬] ^[୪]

2018 ^[୩] ଅଷ୍ଟ୍ରେଲିଆ ଏବଂ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ ବ୍ୟବହାର As of 2019^[update][[Category:Articles containing potentially dated statements from ପ୍ରକାଶନରେ ଅସୁବିଧା: ଅଜଣା ଚିହ୍ନ "୧" ।]] ^[୭] ଅନୁମୋଦିତ ^[୮] ଟାଫେନୋକ୍ଇନ୍ ପ୍ରିମାକାଇନ୍ ସହିତ ଜଡିତ | ^[୯]

ଆଧାର

1 2 Peters W (1999). "The evolution of tafenoquine--antimalarial for a new millennium?". J R Soc Med. 92 (7): 345–352. doi:10.1177/014107689909200705. PMC 1297286. PMID 10615272.
1 2 Use During Pregnancy and Breastfeeding
1 2 3 Haston JC, Hwang J, Tan KR (November 2019). "Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria — United States, 2019" (PDF). MMWR. Morbidity and Mortality Weekly Report. 68 (46): 1062–1068. doi:10.15585/mmwr.mm6846a4. PMID 31751320. Archived from the original (PDF) on 24 March 2021. Retrieved 23 November 2019.
1 2 3 Haston JC, Hwang J, Tan KR (November 2019). "Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria — United States, 2019" (PDF). MMWR. Morbidity and Mortality Weekly Report. 68 (46): 1062–1068. doi:10.15585/mmwr.mm6846a4. PMID 31751320. Archived (PDF) from the original on 24 March 2021. Retrieved 23 November 2019.
1 2 "Tafenoquine Succinate (Krintafel) Monograph for Professionals". Drugs.com. Archived from the original on 7 August 2020. Retrieved 22 November 2019.
1 2 3 4 "Tafenoquine Succinate (Krintafel) Monograph for Professionals". Drugs.com. Archived from the original on 7 August 2020. Retrieved 22 November 2019.
↑ Hounkpatin, Aurore B; Kreidenweiss, Andrea; Held, Jana (March 2019). "Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data". Infection and Drug Resistance. 12: 553–570. doi:10.2147/IDR.S151031.
↑ "Krintafel Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 9 July 2021. Retrieved 22 November 2019.
↑ "Tafenoquine Approved for Malaria Prophylaxis and Treatment". Centers for Disease Control and Prevention (CDC). 25 April 2019. Archived from the original on 9 July 2021. Retrieved 22 November 2019.

[Peters1999-1] 1 2 Peters W (1999). "The evolution of tafenoquine--antimalarial for a new millennium?". J R Soc Med. 92 (7): 345–352. doi:10.1177/014107689909200705. PMC 1297286. PMID 10615272.

[Drugs.com_Pregnancy-2] 1 2 Use During Pregnancy and Breastfeeding

[Jul2019-3] 1 2 3 Haston JC, Hwang J, Tan KR (November 2019). "Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria — United States, 2019" (PDF). MMWR. Morbidity and Mortality Weekly Report. 68 (46): 1062–1068. doi:10.15585/mmwr.mm6846a4. PMID 31751320. Archived from the original (PDF) on 24 March 2021. Retrieved 23 November 2019.

[autogen1-4] 1 2 3 Haston JC, Hwang J, Tan KR (November 2019). "Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria — United States, 2019" (PDF). MMWR. Morbidity and Mortality Weekly Report. 68 (46): 1062–1068. doi:10.15585/mmwr.mm6846a4. PMID 31751320. Archived (PDF) from the original on 24 March 2021. Retrieved 23 November 2019.

[AHFS2019-5] 1 2 "Tafenoquine Succinate (Krintafel) Monograph for Professionals". Drugs.com. Archived from the original on 7 August 2020. Retrieved 22 November 2019.

[autogen3-6] 1 2 3 4 "Tafenoquine Succinate (Krintafel) Monograph for Professionals". Drugs.com. Archived from the original on 7 August 2020. Retrieved 22 November 2019.

[Hou2019-7] Hounkpatin, Aurore B; Kreidenweiss, Andrea; Held, Jana (March 2019). "Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data". Infection and Drug Resistance. 12: 553–570. doi:10.2147/IDR.S151031.

[8] "Krintafel Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 9 July 2021. Retrieved 22 November 2019.

[CDC2019Travel-9] "Tafenoquine Approved for Malaria Prophylaxis and Treatment". Centers for Disease Control and Prevention (CDC). 25 April 2019. Archived from the original on 9 July 2021. Retrieved 22 November 2019.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]